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reduction of rate (-6.9%, -10.1%, and -15.9%) and of the EDD (-9.7%, -20.5%,
-23.2%, respectively, n¼ 4-7) while no differences were observed in the TOP.
MDP and APD values were signiﬁcantly different from control only at the 0.6 mg/ml
dose; in particular APD increased by +15.7% (n¼7) and MDP became less
negative by -6.9% (4.0 mV, n¼7).The time course of the spontaneous rate decrease
proceeded with time constants of 18.4 s, 17.6 s, and 14.2 s for 0.02, 0.2, and 0.6 mg/
ml (n¼4-7), respectively. The effect of the drug was reversible upon wash-out all
concentrations.
Conclusions: Our preliminary experiments provide the ﬁrst evidence that TMYX,
a drug largely used in the treatment of cardiac arrhythmias in TCM, acts as a dose-
dependent spontaneous rate-lowering agent in SAN cells. These preliminary data also
indicate that at doses of 0.2 mg/ml or less, the chronotropic effect reﬂects a selective
action on the early diastolic “pacemaker” depolarization, and thus suggests an effect
on the If current. Since TMYX is a mixture of several pure compounds, we intend to
proceed with the identiﬁcation of the speciﬁc molecule (s) responsible for its chro-
notropic the action.
Financial support from Tianjin Zhongxin Pharmaceutical Group Co. Ltd. Le Ren
Tang Pharmaceutical Factory to MB and DD and from MURST grant PRIN
2010BWY8E9 to DD.
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Estrogen inhibits cardiac hypertrophy via upregulation of B-type natriuretic
peptide expression in primary neonatal cardiomyocytes
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Objectives: The main purpose of this study was to determine whether estrogen could
regulate cardiac B-type natriuretic peptide (BNP) expression and to examine signal
transduction pathway (s) that are involved in this process. The role of estrogen-
induced BNP expression in estrogen’s anti-hyperthrophic effect will be also investi-
gated in this study.
Methods: BNP expression and related signal pathway of neonatal rat ventricular
cardiomyocytes (NRVCs) under estrogen treatment (E2, 0.1nMw10nM) was
analyzed by real-time quantitative PCR, Western-blotting or immunoﬂuorescence.
Phenylephrine (PE) -induced cardiac hypertrophy under estrogen with or without BNP
neutralizing antibody treatment was indicated by immunostain of cardiac troponin I
and real-time quantitative PCR detection of cardiac hypertrophic markers.
Results: Our results conﬁrmed that estrogen treatment induced both cardiac BNP
mRNA transcription (1.890.18 fold vs control, n¼4, P<0.05) and protein
translation (glycosylated proBNP, 3.930.38 fold vs control ; non-glycosylated
proBNP, 1.780.29 fold vs control, n¼4, P<0.05) in a concentration-dependent
manner. Compared with control group, a higher percentage (63.312.2% vs
18.55.8%, n¼3, P<0.01) of BNP expression positive NRVCs was also observed
in estrogen treatment group, as indicated by BNP immunostaining. Our data also
shown that upregulation of BNP expression under estrogen treatment was
accompanied by Akt (2.100.16 fold vs control n¼3, P<0.01) and p38
(1.870.39 fold vs control, n¼3, P<0.05) phosphorylation but not Erk1/2.
Treatment of PI3-kinase/Akt inhibitor LY294002 or p38 MAPK inhibitor
SB203580 decreased the estrogen-induced BNP expression in NRVCs (P<0.05).
Furthermore, while E2 treatment signiﬁcantly reduced PE induced cardiomyocytes
hypertrophy (cell-surface area, PE 2.170.36 fold vs PE+E2; beta-MHC mRNA,
PE 1.760.10 fold vs PE+E2; alpha-Actin mRNA, PE 1.700.21 fold vs PE+E2,
n¼4, P<0.05), BNP speciﬁc neutralizing antibody partially reversed the ability of
estrogen to block phenylephrine-induced cell size enlargement (cell-surface area,
PE+E2+antiBNP vs PE, P>0.05) and hypertrophic marker gene upregulation (beta-
MHC mRNA, alpha-Actin mRNA, PE+E2+antiBNP mRNA, PE+E2+antiBNP vs
PE, P>0.05) in NRVCs.
Conclusions: Our study shows that estrogen enhances intracellular BNP expression in
primary cardiomyocytes. Both PI3-kinase/Akt and p38 MAPK signal pathways were
involved in estrogen-induced BNP expression. Further, our data suggests that BNP
partially mediates estrogen’s anti-hypertrophic effect on cardiomyocytes. Our study
helps to explain the higher BNP level observed in normal cycling women than men
and offers an insight into estrogen-mediated cardioprotection.
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Angiotensin II Promotes Atherogenesis by Increasing the Expression of
Connexin 43 in Dendritic Cells NIE Wencheng, 5
Zhu Jianhua
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Objectives: Angiotensin II contributes to atherogenesis and plaque vulnerability, but
the mechanisms are not fully understood. Dendritic cells are vital in both inﬂammation
and atherogenesis. To study the relationships between angiotensin II, dendritic cells,
and atherosclerosis, we investigated the effects of angiotensin II on the expression of
connexin43 in dendritic cells.
Methods: Treatment with angiotensin II increased connexin43 expression
(P<0.05) and enhanced the induction of connexin43 expression by lipopoly-
saccharide in mouse bone marrow-derived dendritic cells (P<0.05). TheC68 JACC Vol 64/16/Suppl C j Octobpro-atherogenesis effect, were attenuated by the angiotensin II type 1 receptor
blocker valsartan.
Results: In atherosclerotic plaques of mice expressing high levels of endogenous
angiotensin II ApoE-/-, generated by the 2kidney-1clip method, connexin43
expression in dendritic cells was also increased (P<0.01), accompanied by the
upregulation of the dendritic cell maturation marker CD40 (P<0.01) and vulnerable
plaque phenotypes. The in vitro and in vivo effects of angiotensin II on connexin43
expression, as well as the proatherogenesis effect, were attenuated by the angiotensin
II type 1 receptor blocker valsartan.
Conclusions: Angiotensin II may promote atherosclerosis and plaque vulnerability
by increasing the expression of connexin43 in dendritic cells and inducing the
maturation of dendritic cells through the angiotensin II type 1 receptor, thus altering
the inﬂammatory balance in favor of T helper 1 polarization.
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The Ligament of Marshall: a conduit between left stellate ganglion and ventricle
as well as a target for treating long QT syndrome induced by cesium chloride
Wang Songyun, Hong Jiang
Renmin Hospital of Wuhan University
Objectives: Histology and electrophysiology show that the ligament of Marshall
(LOM) is richly innervated by sympathetic and parasympathetic nerves in humans and
animals. However, the effect of LOM ablation on cardiac autonomic nervous system
and ventricular electrophysiology is still unknown. To explore it, we investigate the
impact of LOM ablation on left stellate ganglion (LSG) stimulation induced blood
pressure and ventricular electrophysiology changes as well as cesium chloride (Cs)
induced ventricular arrhythmias.
Methods: In 24 anesthetized mongrel dogs, a left thoracotomy exposed the LSG
and LOM. Step 1: In 6 dogs, the maximal systolic blood pressure percent
change (MSBP%) and ventricular effective refractory period (ERP) change
induced by LSG stimulation were measured before and after LOM ablation. Step
2: 18 dogs were assigned into two groups: the control group (N¼9) and the
LOM ablation group (N¼9). Cs-induced ventricular arrhythmias were recorded
and the concentration of Cs required to induce ventricular tachycardia was
measured.
Results: LOM ablation could markedly attenuate the increase in the MSBP%
and the decrease in ventricular ERP induced by LSG stimulation (P<0.05).
During 50V LSG stimulation, the MSBP% before and after LOM ablation were
54.32% and 26.96%, respectively (P¼0.003). Compared to the control group,
the incidence of Cs-induced ventricular arrhythmias could be signiﬁcantly
decreased and the concentration of Cs required to induce ventricular tachycardia
was signiﬁcantly elevated in the LOM ablation group (1.25 vs 0.75mmol/kg,
P¼0.002).
Conclusions: Ventricular electrophysiology changes induced by LSG stimulation
could be attenuated by LOM ablation. In Cs-induced LQTS model, LOM ablation
could signiﬁcantly decrease the incidence of ventricular arrhythmias and increase the
ventricular tachycardia susceptibility. LOM may act as a conduit between left stellate
ganglion and ventricle as well as a target for treating Cs-induced LQTS.
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The effects of local cardiac sympathetic ablation on ventricular electrical
instability after acute myocardial infarction
Jingjie Li, Jugang Chen, Xiuli Wu, Rui Jiang
The First Afﬁliated Hospital of Harbin Medical University
Objectives: Increased sympathetic activation after acute myocardial infarction (AMI)
is thought to contribute to the potential for fatal arrhythmia. However, whether local
cardiac sympathetic ablation can reduce ventricular arrhythmias (VA) is not known.
The aim of this study was to investigate the impact of the coronary sinus (CS) and
great cardiac vein peripheral nerve ablation on ventricular electrical instability in acute
myocardial infarction dogs.
Methods: Twenty one anesthetized dogs were randomly divided into sham group
(n ¼5) or MI group (MI-placebo group n¼8; MI-ablation group n¼8).The dogs were
ligated with left anterior descending branch for MI induction. The incidence and
duration of VA were monitored for 1h in 1h after ablation. The ventricular effective
refractory period (VERP) and spatial distribution of refractory periods were measured
before creating MI and in 2 h after ablation. Subsequently the ventricular ﬁbrillation
threshold (VFT) was determined in the dogs without spontaneous VF. Finally, the
tissues from around CS and great cardiac vein were removed and indicating nerve by
immumohistochemical staining of tyrosine hydroxylase (TH). Norepinephrine levels
in Coronary Sinus and ventricle tissues Stores as well as infarct size were also
detected during the experiment. The other groups were the same as the MI-ablation
group.
Results: The incidence and duration of VA in MI-ablation group were signiﬁ-
cantly lower than that MI-placebo group (P<0.05), two dogs in only MI-placebo
group died of spontaneous VF. Before creating MI, there were no statistical
differences in the VERP and spatial distribution of refractory periods between
the three groups, whereas the ventricular ERP of infarct size were prolonged
obviously and spatial distribution of refractory periods were decreased when
compared with MI-placebo group in 2 h after ablation (P<0.05), VFT also
showed a increased trend (P>0.05). During the experiment, NE levels from CSer 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
blood were reduced in MI-ablation dogs, but only slight changes in ventricle
tissues Stores and infarct size.
Conclusions: The coronary sinus and great cardiac vein peripheral nerve ablation
reduce the occurrence of VA and improve ventricular electrical stability, with no
obvious effect on heart rate and systemic arterial pressure as well as infarct size.
Therefore, local cardiac sympathetic ablation may protect from ventricular arrhyth-
mias during AMI.
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A Novel Drug-eluting PLLA/ACP Bioabsorbable Scaffold for Coronary
Application: Preliminary Experience in Porcine Coronary Arteries
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Objectives: To assess the safety and biocompatibility of a novel bioabsorbable drug-
eluting PLLA/ACP scaffold for coronary applications.
Methods: A total of 12 stents, half biodegradable drug-eluting stents (BDS, n¼6),
half novel fully bioabsorbable drug-eluting scaffolds [NFBS (PowerStentAbsorb),
n¼6], were randomly implanted into the coronary arteries of 12 pigs. After the
observation by coronary angiography in the 28th day, the pigs were sacriﬁced. Stented
segments were processed for quantitative histomorphometry. Histomorphometric
analysis was performed to evaluate endometrial hyperplasia and endothelialization.
Immunohistochemical assay was applied for expression of NF-kB, a-SM-actin, CD31
and eNOS.
Results: At 28-day follow-up, no in-stent restenosis and stent thrombosis were
detected in either group. The level of VEGF and NO in NFBS group were higher
than that BDS group respectively [ (309.86  49.37) pg/ml vs. (222.04  55.16)
pg/ml, P<0.05; (129.96  9.52) mmol/L vs. (79.55  16.55) mmol /L, P<0.05].
Histological analysis indicated that inﬂammation scores of NFBS group were less
than that of BDS group (1.200.42 vs. 1.700.48, P<0.05), while endotheliali-
zation scores was greater (2.000.47 vs. 1.400.52, P<0.05). No signiﬁcant dif-
ferences in neointimal area percentage. Immunohistochemistry showed that the
expression of eNOS and CD31 in NFBS group were greater than that in BDS group
respectively (38.534.25 vs. 27.533.55, P<0.01) (29.403.84 vs. 19.783.50,
P<0.05), while NF-kB protein expression was less (22.073.18 vs. 28.593.54,
P<0.05). No signiﬁcant differences in PCNA and a-SM-actin level between two
groups.
Conclusions: NFBS based on PLLA and ACP is safe, associated with less inﬂam-
matory response and better endothelialization, improved sufﬁcient biocompatibility.
NFBS is much better than PLLA stent for coronary applications.
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Effects of Astragaloside on Cardiac Function of rats with Cecal Ligation and
Puncture and Underlying Mechanism
Huang Xin, Shi-yu Ma, Xin Yin, Qin Liu, Yan-fen Chen, Min-zhou Zhang,
Li-heng Guo
Guangdong Provincial Hospital of Traditional Chinese Medicine
Objectives: We aimed to investigate the effect of Astragaloside on cardiac function
and to search for possible mechanism in septic rats.
Methods: Fifty male Sprague-Dawley (SD) rats were randomized into Sham-opera-
tion group (Sham group, n¼10), saline group (NS group, n¼20) and Astragaloside
group (AST group, n¼20). Polymicrobial sepsis model was induced by cecal ligation
and puncture (CLP) in NS and AST group. Rats in NS group were injected with saline
(10ml/Kg) 2h after CLP and then once a day for 7 days. Rats in AST group were
injected AST (25mg/Kg) instead of saline at the same time points. Dead time of rats
was recorded every day and Cardiac function was tested by ultrasound. Serum
concentrations of monocyte chemoattractant protein-1 (MCP-1), brain natriuretic
peptide (BNP) and cardiac troponin I (cTnI) was observed. The left ventricle samples
were reserved for histomorphology. Myocardial apoptosis on the left ventricle were
detected by TUNEL staining in situ, and the changes of Bcl-2 and Bax protein were
detected by werstern blot. Meanwhile, the expression of iNOS, AMPK mRNA and
protein were tested.
Results: On day 7 after CLP, 3 out of 20 AST treated rats survived, but all rats in NS
group died. Compared with the NS group, AST group could obviously increase
ejection fraction (EF) (57.95.66 vs 70.64.02, P<0.05) but decrease the left ven-
tricular internal dimension in systole (LVIDs) (4.450.35 vs 3.440.27, P<0.05) and
MCP-1, BNP, cTnI release in serum (104.86.5 vs 89.748.2, 2.790.21 vs
2.240.17, 1.380.07 vs 0.910.05, P<0.05). Correspondingly, histomorphology
indicated that myocardial inﬂammation of AST group was comparatively mild. Also,
AST treated rats signiﬁcantly decreased myocardial apoptosis index and the expres-
sion of Bax protein was obviously decreased but markedly increased the expression of
Bcl-2 protein. Meanwhile, the mRNA expression of iNOS and AMPK in AST treated
rats was obviously increased.
Conclusions: AST could effectively extend the survival time, signiﬁcantly as-
suage the cardiac function and decrease myocardial necrosis and apoptosis inJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Bseptic rats indused by CLP, which may be relative with the expression of iNOS
and AMPK.
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Carboxyl-terminal polypeptide of Cardiotrophin-1 promoted cardiac
hypertrophy and induced myocardial remodeling in Kunming mice
Chen Shufen1, Wei Zhang2, Tao-Zhi Wei3, Li-Ya Rao3, Ming-Guang Xu4,
Zhan-Ling Dong4
1Central Clinical Laboratory, Afﬁliated Hospital of Hainan Medical University,
Haikou 570102, 2Department of Cardiology Medicine, People’s Hospital in Hainan
Sanya, Sanya 572000, 3Department of Cardiology Medicine, Union Hospital, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan 430022,
4Department of Physiology, Hainan Medical University, Haikou 571101
Objectives: To study histiocytic characteristics of myocardial remodeling induced by
chronic exposure to cardiotrophin-1 in Kunming mice.
Methods: Sixteen amino acids from carboxyl-terminal of mouse CT-1 were selected
and synthesized to a polypeptide (Carboxyl-terminal polypeptide of Cardiotrophin-1,
CT-1-CP), and then were injected intraperitoneally to the Kunming mice for 1 to 4
weeks (4 groups; n¼10, 5 male), the control group (n¼10, 5 male) received intra-
peritoneal injection of physiological saline for 4 weeks. At every end point of injection
the body and heart were weighted, and the hearts tissues samples were isolated and
embedded in parafﬁn for preparing tissue section. The HE and MASSON staining
were used for dynamic morphological histological analysis.
Results: The increase of body weight at ﬁrst and second week was higher in the
control group than that of the CT-1-CP-injected groups, but was signiﬁcantly
lower than that of the latter at third (t¼4.821, P<0.01) and forth week (t¼2.019,
P<0.05). and the body weight of the four-week group had exceeded slightly the
control group; The heart weight of mice in CT-1-CP-injected groups were higher
than that of the control group, but the heart to body weight ratio has no signiﬁcant
difference among them (F¼1.0833, P > 0.05). Intraperitoneal injection of CT-
1-CP one weeks later, the mice began to appear enlarging of ventricular cavity
and thinning of the ventricular wall, and the derangement myoﬁbril and the
blurred cross striation complicated with uneven staining of cytoplasm, which were
scattered in the ventricular wall, were detected. After 2 weeks, the anatomical
change of ventricles became deteriorated and local hypertrophy of ventricular wall
appeared, and the focuses of pathological changes of cardiomyocytes increased. 3,
4 weeks later, the lesion was more obvious and the scope of focuses gradually
expanded. In focuses with serious pathological change some myoﬁbrils were
fragmented and some sarcomeres were partially or wholly lost. Masson staining
also shows exaggerated growth of the ﬁbril-connective tissues surrounding
myoﬁbrils and in the spaces where the myoﬁbril array disturbed or sarcomere
defected.
Conclusions: Long-term exposure to CT-1-CP could promote cardiac hypertrophy
and lead to cardiac remodeling in Kunming mice as well as the ultrastructure damage
of cardiomyocyte in remodeled myocardial tissues, otherwise, induced the hyperplasia
of ﬁbril-connective tissues.
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Inhaled budesonide for the prevention of acute mountain sickness in
unacclimatization young men: a double-blind randomized controlled trial
Li xiangjun, Huang lan
Cardiovascular Department of Xinqiao Hospital, Third Military Medical University
Objectives: Oral glucocorticoids can prevent Acute Mountain Sickness (AMS);
however, these drugs are associated with multiple systemic side effects. The effects of
inhaled Budesonide, an alternative AMS therapy, remain unknown.
Methods: The 80 healthy young male plain residents (17w33 years old) were
recruited. Potential participants were excluded if they had a high altitude (> 2500 m)
exposure history in the last year or organic diseases such as congenital heart disease,
arrhythmia, liver or kidney dysfunction, psychological or neurological disorder. The
subjects were randomly assigned to receive inhalation of budesonide (BUD, 200 mg,
bid), procaterol tablet (PT, 25 mg, bid), inhalation of budesonide/fomoterol (BUD/FM,
160 mg/4.5 mg, bid) or placebo (1 tablet, bid) (n ¼ 20 subjects, respectively). Subjects
began treatment three days before an ascent to 3700 m from 500 m plain within 2.5 h
by air. The treatment stopped after arrival. The Lake Louis AMS questionnaire, blood
pressure (BP), heart rate (HR), and oxygen saturation (SpO2) were scored at 20 h, 72
h, and 120 h following exposure to high altitude. Pulmonary function was measured
after 20 h exposure.
Results: Compared with placebo, BUD reduced the incidence of AMS (70% vs. 25%
at 20 h after exposure, P< 0.05; 10% vs. 5% at 72 h, P > 0.05; 10% vs. 5% at 120 h,
P > 0.05) without side effects, relative risk is 0.357, and the attributable risk is
0.45. SpO2 was higher in BUD, BUD/FM and PT groups compared to placebo at 20 h
(P ¼ 0.0001). All subjects’ SpO2 dropped following ascent (98.1% to 88.12%,
P< 0.01) and increased gradually but still lower at 120 h than that at plain
(92.04% vs. 98.1%, P< 0.01). Pulmonary function was not different among the four
groups at 20 h. There was no HAPE or HACE reported.
Conclusions: BUD can prevent AMS without side effects. The alleviation of AMS
may be related to increased SpO2 rather than pulmonary function.
The registration number of this clinical trial was ChiCTR-PRC-12002748.asic and Translational Medicine C69
